Physician profile
Syed Khalid
NPI 1770586638
$635.97
in general payments reported to CMS, 2019-2025
14 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.47 · 2021: $28.18 · 2022: $70.95 · 2023: $85.33 · 2024: $116 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $443 · Education: $54.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $443.02 |
| Education | $54.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $261.87 | 2022-2025 | |
| Enterra Medical, INC. | $89.96 | 2025 | |
| Nestle Healthcare Nutrition INC. | $46.28 | 2023 | |
| Janssen Biotech, INC. | $39.48 | 2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $32.48 | 2022 | |
| Pfizer INC. | $30.40 | 2024 | |
| Mis Implants Technologies, INC. | $25.53 | 2019 | |
| Celltrion USA INC. | $23.95 | 2024 | Zymfentra |
| Ipsen Biopharmaceuticals, INC | $22.75 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $21.15 | 2023 | |
| Ironwood Pharmaceuticals, INC | $16.11 | 2021 | |
| Merck Sharp & Dohme LLC | $13.94 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.07 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,623.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.